Direktnyheter • May 10
Jade Biosciences to Present Phase 1 JADE101 Data and Advance Clinical Pipeline Through 2027 Jade Biosciences reported first quarter 2026 results and outlined upcoming clinical milestones across its pipeline. Interim biomarker-rich Phase 1 data for lead asset JADE101 will be presented at the 63rd European Renal Association Congress. The company plans to start a Phase 2 trial of JADE101 in IgA nephropathy in Q2 2026, a Phase 1 trial for JADE201 in Q2 2026, and a Phase 1 trial for JADE301 in the first half of 2027.
For you as an investor, the key takeaway is that Jade Biosciences is moving several kidney-focused programs through early-stage development, with specific start dates and interim data timelines laid out through 2027. The upcoming presentation of biomarker-rich Phase 1 data for JADE101 could help clarify how the drug behaves in humans and how relevant it may be for IgA nephropathy before larger, longer trials begin.
The outlined schedule for JADE201 and JADE301 suggests a pipeline that is still in early clinical stages, which typically comes with higher scientific and regulatory uncertainty. At the same time, having multiple programs progressing on a defined timetable can spread development risk across different assets and indications. As you follow this stock, the quality and detail of the clinical updates at conferences and in future releases will likely be more important than the dates themselves. Tillkännagivande • May 08
Jade Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Jade Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Apr 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$167m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Tillkännagivande • Apr 24
Jade Biosciences, Inc. Appoints Edward R. Conner, as Chief Medical Officer, Effective April 22, 2026 Jade Biosciences, Inc. announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer, effective April 22, 2026. Dr. Conner is an accomplished biopharmaceutical executive with extensive experience spanning clinical development, translational medicine, regulatory strategy and mechanism-based drug development, across early- to late-stage programs. As Chief Medical Officer, he will lead Jade’s clinical and medical organization, overseeing development strategy and data generation to support the advancement of the Company’s differentiated pipeline of potentially disease-modifying therapies for autoimmune diseases. Dr. Conner joins Jade from Ardelyx, Inc. where he served as CMO. Prior to Ardelyx, he was CMO of Third Harmonic Bio and previously served as CMO of Locanabio. Earlier, he served as Site Lead and Division Head of Medical and Development for Astellas Gene Therapies (formerly Audentes Therapeutics). Prior to Astellas’ acquisition of Audentes, he was CMO and Senior Vice President of Audentes Therapeutics, where he led clinical development and operations, medical affairs, regulatory, drug safety and patient advocacy. Before Audentes, Dr. Conner served as CMO of Sangamo Therapeutics. Earlier in his career, he was a Medical Director at Genentech, Inc. (a member of the Roche Group), where he led clinical development programs for XOLAIR® (omalizumab) in chronic urticaria and allergic asthma. Dr. Conner received his M.D. from the University of California, San Francisco. He completed his residency in internal medicine at the University of Michigan and a fellowship in clinical immunology and allergic diseases at Johns Hopkins School of Medicine. He holds a B.S. in biology from Duke University. Tillkännagivande • Apr 21
Jade Biosciences, Inc., Annual General Meeting, Jun 09, 2026 Jade Biosciences, Inc., Annual General Meeting, Jun 09, 2026. New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$47m). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$144m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Tillkännagivande • Nov 09
Jade Biosciences, Inc. Presents New Data Demonstrating A Favorable Preclinical Safety Profile of Jade101 and a Translational Analysis of April Mediated Biomarker Responses At the American Society of Nephrology Kidney Week 2025 Jade Biosciences, Inc. presented two posters for JADE101, its investigational anti-A PRol proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is designed to selectively inhibit APRIL, a key driver of pathogenic IgA production in IgAN, a progressive autoimmune disease that frequently leads to end-stage kidney disease over a patient's lifetime. Biomarker responses to JADE101 in the ongoing healthy volunteer study are anticipated to define dose and dose interval selection for future clinical trials in IgAN patients: Analyses demonstrated that in vitro APRIL binding affinity is predictive of in vivo IgA-lowering potency across NHP and human data sets, supporting that high APRIL binding affinity results in potent IgA reduction in vivo in NHPs and humans. Clinical observations from healthy volunteers further demonstrate that high APRIL binding affinity is a key determining of the magnitude and duration of free APRIL and IgA reduction at a given anti-APRIL dose level. Pharmacokinetic and free APRIL suppression profiles of anti-APRIL monoclonal antibodies were consistent between healthy volunteers and patients with IgAN, supporting the use of healthy volunteer PK and biomarker results for dose selection in IgAN patients. Its differentiated pharmacokinetic and pharmacodynamic profile supports the potential for infrequent and convenient subcutaneous dosing, an important consideration for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. A Phase 1 randomized, double-blind, placebo-controlled clinical trial evaluating single ascending subcutaneous dosing of JADE101 in healthy adult volunteers is ongoing. The Company expects data from the Phase 1 trial to define dose and dosing interval selection for later-stage studies, based on biomarker responses associated with optimal clinical activity in IgAN patients. Tillkännagivande • Sep 09
Jade Biosciences, Inc. Announces Departure of Hetal Kocinsky as Chief Medical Officer, Effective September 9, 2025 Effective September 9, 2025, Hetal Kocinsky, M.D. departed from her position as Chief Medical Officer of Jade Biosciences, Inc. (the “Company”). The Company expects to enter into a separation agreement with Dr. Kocinsky. Under the separation agreement, subject to the Company’s receipt of a general release of claims against the Company, Dr. Kocinsky will receive (i) a one-time payment equal to 12 months of her current base salary and (ii) a cash payment equal to the premiums payable by Dr. Kocinsky for continuation coverage under COBRA for a period of 12 months. The Company’s scientific and clinical programs will continue to be led by Dr. Andrew King, Ph.D, Chief Scientific Officer and Head of Research & Development. Tillkännagivande • Sep 04
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101 Jade Biosciences, Inc. announced that it has dosed the first cohort of participants in a Phase 1 healthy volunteer trial of JADE101. JADE101 is the Company's investigational monoclonal antibody designed to selectively inhibit the activity of A PRol proliferation-Inducing Ligand (APRIL) in patients with immunoglobulin A nephropathy (IgAN). The Company expects interim Phase 1 clinical data in the first half of 2026. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study evaluating single ascending subcutaneous doses of JADE101 in healthy adult volunteers. The trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of JADE101. Its differentiated pharmacokinetic and pharmacodynamic profile supports the potential for infrequent and convenient subcutaneous dosing, an important consideration for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. Tillkännagivande • Jul 02
Jade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer Jade Biosciences, Inc. on July 1, 2025, announced the appointment of Brad Dahms as Chief Financial Officer. Mr. Dahms was most recently Chief Financial Officer and Chief Business Officer of IDRx, where he led financial operations, investor relations, and business development, including its transition to a public-ready company and sale to GSK for up to $1.15 billion. Prior to that, he served as Chief Financial Officer of Theseus Pharmaceuticals, where he guided the company’s initial public offering and sale to Concentra Biosciences. Earlier, as Chief Financial Officer of Selecta Biosciences, he played a central role in securing several financings and led multiple strategic partnerships. Across these roles, Mr. Dahms consistently led core functions spanning finance, business development, information technology, and investor and public relations. He began his career in healthcare investment banking, holding roles at Cantor Fitzgerald, RBC Capital Markets, and J.P. Morgan. Mr. Dahms earned a B.S. in Economics, with honors, from The Ohio State University. Tillkännagivande • Jun 10
Jade Biosciences Presents Jade101 Preclinical Data At the 62nd European Renal Association Congress Demonstrating Potential for Best-In-Class Profile in IgA Nephropathy Jade Biosciences, Inc. announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. The findings, presented during a oral session at the 62nd Europe Renal Association (ERA)Congress, support advancement of JADE 101 into a planned healthy volunteer study In the second half of 2025. F favorable subcutaneous profile in NHPs: Following a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formation: JADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibody. JADE101 plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025; JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025.; These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade's product candidates may failure in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully fully developed. The JADE101 is a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, and the other risks, uncertainties, and factors more fully developed. The findings, presented during the 62nd European Renal association Congress, support advancement of Jade101 into a planned healthy volunteer Study in the second half of 2025, and the results of JADE101. Tillkännagivande • Jun 02
Jade Biosciences, Inc. to Present New Preclinical Data on Jade101 At the 62nd European Renal Association Congress Jade Biosciences, Inc. announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered during the Focused Oral Session on Glomerular and Tubulo-stitial Diseases. Session details are as follows: Session Title: Glomerular and Tubulo -interstitial Diseases. Presenter:Erin Filbert, Executive Director, Head of Research and Translational Medicine, Jade Biosciences. Presentation Type: Focused Oral; Room: Focused Oral Room 2; Date and Time: Friday, June 6, 2025, at 4:30 p.m. CET. Board Change • Apr 30
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
